Postmenopausal women already have a broad menu of locally administered estrogen therapy products to treat vulvar and vaginal atrophy.
XBiotech's efforts to shade Xilonix's clinical failings amounted to little more than hand waving when it mattered most. European regulators at the oral explanation meeting on Thursday were not fooled.
Tesaro's newly approved PARP inhibitor Zejula is really 50% more expensive than its list price implies.
Alpine Immune Sciences, a cancer immunotherapy company founded by former Dendreon CEO Mitch Gold, is listing publicly through a merger with Nivalis Therapeutics.